Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hung-Jen Shao is active.

Publication


Featured researches published by Hung-Jen Shao.


Scientific Reports | 2016

Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients

Wen-Sy Tsai; Jinn-Shiun Chen; Hung-Jen Shao; Jen-chia Wu; Jr-Ming Lai; Si-Hong Lu; Tsung-Fu Hung; Yen-Chi Chiu; Jeng-Fu You; Pao-Shiu Hsieh; Chien-Yuh Yeh; Hsin-Yuan Hung; Sum-Fu Chiang; Geng-Ping Lin; Reiping Tang; Ying-Chih Chang

Enumeration of circulating tumor cells (CTCs) has been proven as a prognostic marker for metastatic colorectal cancer (m-CRC) patients. However, the currently available techniques for capturing and enumerating CTCs lack of required sensitivity to be applicable as a prognostic marker for non-metastatic patients as CTCs are even more rare. We have developed a microfluidic device utilizing antibody-conjugated non-fouling coating to eliminate nonspecific binding and to promote the multivalent binding of target cells. We then established the correlation of CTC counts and neoplasm progression through applying this platform to capture and enumerate CTCs in 2 mL of peripheral blood from healthy (n = 27), benign (n = 21), non-metastatic (n = 95), and m-CRC (n = 15) patients. The results showed that the CTC counts progressed from 0, 1, 5, to 36. Importantly, after 2-year follow-up on the non-metastatic CRC patients, we found that those who had ≥5 CTCs were 8 times more likely to develop distant metastasis within one year after curable surgery than those who had <5. In conclusion, by employing a sensitive device, CTC counts show good correlation with colorectal neoplasm, thus CTC may be as a simple, independent prognostic marker for the non-metastatic CRC patients who are at high risk of early recurrence.


PLOS ONE | 2016

Sensitive and Specific Biomimetic Lipid Coated Microfluidics to Isolate Viable Circulating Tumor Cells and Microemboli for Cancer Detection

Jia-Yang Chen; Wen-Sy Tsai; Hung-Jen Shao; Jen-chia Wu; Jr-Ming Lai; Si-Hong Lu; Tsung-Fu Hung; Chih-Tsung Yang; Liang-Chun Wu; Jinn-Shiun Chen; Wen-Hwa Lee; Ying-Chih Chang

Here we presented a simple and effective membrane mimetic microfluidic device with antibody conjugated supported lipid bilayer (SLB) “smart coating” to capture viable circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) directly from whole blood of all stage clinical cancer patients. The non-covalently bound SLB was able to promote dynamic clustering of lipid-tethered antibodies to CTC antigens and minimized non-specific blood cells retention through its non-fouling nature. A gentle flow further flushed away loosely-bound blood cells to achieve high purity of CTCs, and a stream of air foam injected disintegrate the SLB assemblies to release intact and viable CTCs from the chip. Human blood spiked cancer cell line test showed the ~95% overall efficiency to recover both CTCs and CTMs. Live/dead assay showed that at least 86% of recovered cells maintain viability. By using 2 mL of peripheral blood, the CTCs and CTMs counts of 63 healthy and colorectal cancer donors were positively correlated with the cancer progression. In summary, a simple and effective strategy utilizing biomimetic principle was developed to retrieve viable CTCs for enumeration, molecular analysis, as well as ex vivo culture over weeks. Due to the high sensitivity and specificity, it is the first time to show the high detection rates and quantity of CTCs in non-metastatic cancer patients. This work offers the values in both early cancer detection and prognosis of CTC and provides an accurate non-invasive strategy for routine clinical investigation on CTCs.


Biomicrofluidics | 2014

Efficient elusion of viable adhesive cells from a microfluidic system by air foam

Jr-Ming Lai; Hung-Jen Shao; Jen-chia Wu; Si-Hong Lu; Ying-Chih Chang

We developed a new method for releasing viable cells from affinity-based microfluidic devices. The lumen of a microchannel with a U-shape and user-designed microstructures was coated with supported lipid bilayers functionalized by epithelial cell adhesion molecule antibodies to capture circulating epithelial cells of influx solution. After the capturing process, air foam was introduced into channels for releasing target cells and then carrying them to a small area of membrane. The results show that when the air foam is driven at linear velocity of 4.2 mm/s for more than 20 min or at linear velocity of 8.4 mm/s for more than 10 min, the cell releasing efficiency approaches 100%. This flow-induced shear stress is much less than the physiological level (15 dyn/cm(2)), which is necessary to maintain the intactness of released cells. Combining the design of microstructures of the microfluidic system, the cell recovery on the membrane exceeds 90%. Importantly, we demonstrate that the cells released by air foam are viable and could be cultured in vitro. This novel method for releasing cells could power the microfluidic platform for isolating and identifying circulating tumor cells.


Archive | 2017

METHODS AND SYSTEMS FOR CANCER DIAGNOSIS AND PROGNOSIS

Ying-Chih Chang; Jr-Ming Lai; Jen-chia Wu; Huai-Lu Chen; Hung-Jen Shao; Si-Hong Lu; Tsung-Fu Hung; Huangpin Ben Hsieh


The Journal of Urology | 2018

MP40-20 NOVEL CIRCULATING TUMOR CELLS BLOOD ASSAY FOR THE CLARIFICATION OF 4-10 NG/ML PSA RESULTS ASSESSED IN A PROSPECTIVE CLINICAL STUDY

See-Tong Pang; Ying-Hsu Chang; Po-Hung Lin; Ying-Chih Chang; Drew Watson; Oscar Segurado; Si-Hong Lu; Jen-chia Wu; Hung-Jen Shao; Jr-Ming Lai; Shih-En Chang; Ben Hsieh; Mana Jarvey; Mahul B. Amin; Rui Mei


Journal of Clinical Oncology | 2018

Therapy selection and monitoring of early and late stage non small cell lung cancer (NSCLC) using a novel circulating tumor cells (CTCs) PD-L1 blood test.

Yen-Lin Chen; Wen-Jie Huang; Bruce K. Patterson; Amanda Chargin; Chia-Hsin Hsieh; Ruey Kuen Hsieh; Mahul B. Amin; Oscar Segurado; Hung-Jen Shao; Feng-Ming Lin; Shih-En Chang; Jen-chia Wu; Jr-Ming Lai; Ben Hsieh; Mana Javey; Rui Mei


Journal of Clinical Oncology | 2018

A novel circulating tumor cell blood test for early detection of colorectal, prostate, and breast cancers: Results from 709 samples.

Ashish Nimgaonkar; Oscar Segurado; Wen-Sy Tsai; See-Tong Pang; Ming-Feng Hou; Ying Chang; Drew Watson; Ying-Hsu Chang; Po-Hung Lin; Jen-chia Wu; Hung-Jen Shao; Jr-Ming Lai; Feng-Ming Lin; Si-Hong Lu; Shih-En Chang; Ben Hsieh; Mana Javey; Rui Mei


Journal of Clinical Oncology | 2018

Prospective clinical study of a prostate cancer (PCa) rule-out blood test for PSA gray zone patients using a sensitive circulating tumor cell assay.

See-Tong Pang; Ying-Hsu Chang; Po-Hung Lin; Ying Chang; Drew Watson; Oscar Segurado; Si-Hong Lu; Jen-chia Wu; Jr-Ming Lai; Hung-Jen Shao; Shih-En Chang; Ben Hsieh; Mana Javey; Rui Mei


Journal of Clinical Oncology | 2018

Prospective clinical study of circulating tumor cells for colorectal cancer screening.

Wen-Sy Tsai; Ashish Nimgaonkar; Oscar Segurado; Ying Chang; Ben Hsieh; Hung-Jen Shao; Jen-chia Wu; Jr-Ming Lai; Mana Javey; Drew Watson; Rui Mei


Cancer Research | 2018

Abstract 2223: Analytical validation of a novel circulating tumor cell platform (CMx) for early detection of cancer

Hung-Jen Shao; Huangpin B. Hsieh; Wen-Sy Tsai; Jen-chia Wu; Jr-Ming Lai; Shih-En Chang; Mana Javey; Oscar Segurado; Mahul B. Amin; Ashish Nimgaonkar; Rui Mei

Collaboration


Dive into the Hung-Jen Shao's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Drew Watson

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar

Wen-Sy Tsai

Memorial Hospital of South Bend

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mahul B. Amin

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge